Setd3: A Potential Drug Target and Biomarker (G84193)

Target Name: SETD3

NCBI ID: G84193

SETD3

Setd3: A Potential Drug Target and Biomarker

Setd3 is a gene that encodes for actin-histidine N-methyltransferase (ISOFORM B), a protein that is involved in a variety of cellular processes, including cell signaling, DNA replication, and protein stability. The study of Setd3 and its potential functions as a drug target or biomarker has become increasingly interested in recent years.

The Role of Setd3 in Cellular Signaling

Setd3 is a key player in the regulation of actin, a protein that plays a critical role in the structure and function of cells. In many organisms, actin is modified by the addition of histidine, which can influence a variety of cellular processes. Setd3 is responsible for the N-methylation of the actin protein, which modifies its stability, localization, and interaction with other cellular components.

The regulation of actin by Setd3 is critical for the proper functioning of many cellular processes. For example, in the regulation of cell division, actin is involved in the formation of the cytoskeleton and the distribution of chromosomes during the cell cycle. In addition, actin is also involved in the regulation of cell signaling, as many signaling pathways rely on the interaction between proteins and actin.

The Potential Role of Setd3 as a Drug Target

The study of Setd3 as a drug target is an exciting area of research, as it has the potential to treat a variety of diseases. Many diseases are characterized by the over-expression or under-expression of specific genes, and Setd3 is one of these genes that has been well-studied.

One of the promising aspects of Setd3 as a drug target is its involvement in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, Setd3 has been shown to be overexpressed in a variety of cancer types, including breast, ovarian, and prostate cancer. Additionally, Setd3 has also been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

In addition to its involvement in disease, Setd3 also has potential as a biomarker for disease diagnosis and monitoring. The N-methylation of actin is a well-established biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. By studying the expression and function of Setd3, researchers may be able to develop new diagnostic tests or monitoring tools for these diseases.

The Potential Role of Setd3 as a Biomarker

The study of Setd3 as a biomarker for disease has the potential to revolutionize the field of diagnostic biomarkers. Setd3 has been shown to be involved in the regulation of many cellular processes, including cell signaling and DNA replication. As such, it has the potential to serve as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the key advantages of Setd3 as a biomarker is its stability and ease of detection. The N-methylation of actin is a stable modification that can be detected using a variety of techniques, including RNA sequencing and western blotting. This makes it an attractive option for use as a diagnostic biomarker.

In addition, the potential of Setd3 as a biomarker is based on a large number of studies that have demonstrated its involvement in the regulation of many cellular processes. For example, several studies have shown that Setd3 is involved in the regulation of cell signaling, DNA replication, and protein stability. These findings provide strong evidence for the potential of Setd3 as a biomarker for a variety of diseases.

Conclusion

In conclusion, Setd3 is a gene that encodes for actin-histidine N-methyltransferase (ISOFORM B), a protein that is involved in a variety of cellular processes

Protein Name: SET Domain Containing 3, Actin Histidine Methyltransferase

Functions: Protein-histidine N-methyltransferase that specifically mediates 3-methylhistidine (tele-methylhistidine) methylation of actin at 'His-73' (PubMed:30526847, PubMed:30626964, PubMed:30785395, PubMed:31388018, PubMed:31993215). Histidine methylation of actin is required for smooth muscle contraction of the laboring uterus during delivery (PubMed:30626964). Does not have protein-lysine N-methyltransferase activity and probably only catalyzes histidine methylation of actin (PubMed:30626964, PubMed:30785395, PubMed:31388018)

The "SETD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets